Spine Biologics Market Research Report Information By Product (Bone Allografts, Bone Graft Substitute, Platelet Rich Plasma, And Bone Marrow Aspirate Therapy), By Surgery Type (Anterior Cervical Discectomy And Fusion (ACDF), Transforamenal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), and Lateral Lumbar Interbody Fusion (LLIF)), By End User (Hospitals, Spinal Surgery Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Spine Biologics Market Overview

The Spine Biologics Market Size was valued at USD 2.8 Billion in 2022 and is projected to grow from USD 2.9 Billion in 2023 to USD 4.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.90% during the forecast period (2023 - 2032). Growing numbers of elderly people and an increase in the frequency of spine abnormalities, are the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Spine Biologics Market Trends

• Growing geriatric population is driving the market growth

The global market is primarily being driven by the aging population, an increase in the occurrence of spine abnormalities, and technological developments in bone grafting methods. Additionally, increasing rates of minimally invasive procedures being preferred and rising occurrences of degenerative spine ailments are both driving the market's expansion. Additionally, interbody fusion and direct lateral interbody fusion are the two cutting-edge biological techniques that are most often used by surgeons worldwide to treat spinal deformities.

The use of lateral body fusion, a minimally invasive operation that takes use of recent advancements in biomaterials, is the perfect method for treating spinal diseases since it produces fewer complications and allows for a quick and safe recovery. In the treatment of disc generation, sclerosis, and other spine-related illnesses, it further increases the demand for spine biologics. The elderly population is expanding worldwide, which will increase the demand for treatment and diagnosis of the problems. Spine injuries are highly common among people over 50 because they are more likely to have structural changes in the spine or spinal impairments. The market for spine biologics will therefore be driven by the aforementioned reasons during the predicted timeframe. The primary reasons propelling the market growth of the spine biologics are the rise in degenerative spine disorders cases and the marked rise in treatment rates around the world.

The market for spine biologics is growing quickly due to technological developments in bone grafting methods, the significance of these biologics in spine surgery, and the increased desire for minimally invasive procedures. The increased acceptance of biomaterials due to their quick healing, short recovery times, and capacity to stimulate cellular growth as well as their high utilization in the treatment of degenerative disc disorders, spinal cord injuries, and bone fusion procedures have a significant impact on the spine biologics industry. Additionally, the market for spine biologics is positively impacted by the aging population's growth, rising awareness of newly established spine treatment methods, research and development initiatives, and an increase in healthcare spending. Thus, driving the Spine Biologics market revenue.

Spine Biologics Market Segment Insights

Spine Biologics Product Insights

The Market segments of Spine Biologics, based on Product includes bone allografts, bone graft substitute, platelet rich plasma, and bone marrow aspirate therapy. In 2022, bone allografts dominated the market as a whole due to the multiple advantages of using them. Allografts are being used more frequently than autografts due to their advantages in terms of osteoconductivity and quick structural support. Additionally, allografts save surgical time and speed up wound healing because no additional surgery is needed to collect the bone. Natural bone transplants are taken from the body of the patient or a donor. Natural bone grafts (xenografts) are provided by businesses like Zimmer Biomet.

Spine Biologics Surgery Type Insights

The Spine Biologics Market segmentation, based on Surgery Type, includes anterior cervical discectomy and fusion (ACDF), transforamenal lumbar interbody fusion (TLIF), anterior lumbar interbody fusion (ALIF), and lateral lumbar interbody fusion (LLIF). In 2022, the and transforaminal lumbar interbody fusion (TLIF) segment contributed significantly to the worldwide market of spine biologics. Treatment for nerve root or spinal cord compression is a surgical treatment that is safe and effective with comparatively infrequent and tolerable consequences. This particular kind of neck surgery entails the removal of a damaged disc followed by intervertebral fusion to stabilize the affected vertebrae and relieve pressure on the spinal cord and nerve roots in the cervical spine. The market is expanding as a result of the rise in cervical cancer cases.

Spine Biologics End User Insights

The Market segmentation of Spine Biologics, based on end user, includes hospitals, spinal surgery centers, and others. In 2022, the hospital sector had the biggest revenue share, and it is projected that this pattern will hold throughout the forecast period. A growth in the number of spine fusion procedures carried out in these hospitals is the main factor driving the market. High hospitalization expenditures, however, have resulted in declining hospital admissions recently, while the number of outpatient visits has increased. In the upcoming years, this is probably going to pose a danger to the use of spine biologics in hospital settings.

Figure 1: Spine Biologics Market, by End User, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Spine Biologics Regional Insights

By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The highest market share (45.80%) for spine biologics worldwide belongs to North America. The rise in prevalence of spine ailments like spinal stenosis, disc-related problems, and spondylolisthesis as well as sustained economic growth are all factors contributing to the market's expansion. The National Spinal Cord Injury Statistical Center estimates that in 2017, there were around 285,000 spinal cord injuries reported in the United States. Further, the U.S. market of Spine Biologics held the largest market share, and the Canada market of Spine Biologics was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil

Figure 2: SPINE BIOLOGICS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Spine Biologics market, is anticipated to experience encouraging expansion during the forecast period. The market expansion in this area is largely being driven by technological advancements, an increase in hospitals, and an expanding patient base for spine biologics. Further, the German market of Spine Biologics held the largest market share, and the UK market of Spine Biologics was the fastest growing market in the European region.

The Asia-Pacific Spine Biologics market is expected to grow at the fastest CAGR from 2023 to 2032, Due to a huge patient base and increased knowledge of the advantages of biologics among patients and surgeons. The regional market is being driven by factors like the region's improved infrastructure and healthcare facilities, rising healthcare costs, and the high prevalence of spine injuries, particularly those brought on by auto accidents. Obesity prevalence has increased due to sedentary lifestyles and shifting lifestyle habits, which will likely continue to drive the industry in the years to come. Further, China’s market of Spine Biologics held the largest market share, and the Indian market of Spine Biologics was the fastest growing market in the Asia-Pacific region.

Spine Biologics Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their Product lines, which will help the market of Spine Biologics, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Spine Biologics industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Spine Biologics industry to benefit clients and increase the market sector. In recent years, the Spine Biologics industry has offered some of the most significant advantages to medicine. Major players in the Spine Biologics market, including Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc., NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC, are attempting to increase market demand by investing in research and development operations.

RTI Surgical (RTI) is a major global private-label OEM that supports patients and top medical technology firms by offering turnkey services for product development and life cycle management. We offer partners in a wide range of market areas, including but not limited to dental, plastic and reconstructive surgery, sports medicine, spine, trauma, and urology/urogynecology, using our expertise in tissue and biologics. Aziyo Biologics and RTI Surgical Holdings, Inc., a global provider of surgical implants, entered into an agreement in August 2018 under which Aziyo offered ViBone, a bone repair product with autograft capabilities, to RTI Surgical for use in a range of orthopedic surgeries.

A manufacturer of medical devices, Orthofix Medical Inc. (Orthofix), formerly known as Orthofix International NV, offers reconstruction and regenerative musculoskeletal solutions to doctors all over the world. Products for fracture management, regenerative products and tissue forms, paediatric and limb reconstruction, motion preservation and fixation implant devices, and foot and ankle products are among the company's top offerings. In order to reach hospitals, doctors, integrated health delivery systems, ambulatory surgery centers, and other purchasing groups worldwide, Orthofix markets its products both directly and through a network of distributors. In addition to the US, UK, Brazil, Italy, France, and Germany, it also has facilities there. United States-based Orthofix is based in Lewisville, Texas. A world-leading spine and orthopedic company with a focus on orthopedics and spine surgery, Orthofix, a global medical device company, and SeaSpine, a global medical technology company, entered into a definitive merger agreement in October 2022. With the addition of highly complementary biologics, the combined entity would become a leading surgical navigation system.

Key Companies in the market of Spine Biologics include

• Arthrex, Inc.


• Cesca Therapeutics Inc.


• DePuy Synthes


• Orthopaedic Seminar


• Exactech, Inc.


• K2M, Inc.


• Lattice Biologics Ltd


• Medtronic


• NuTech Spine, Inc.


• NuVasive Inc.


• Orthofix Holdings, Inc.


• Regen Lab USA LLC


• RTI Surgical Holdings, Inc.


• Stryker


• Wright Medical Group N.V.


• XTANT MEDICAL


• Zimmer Biomet


• Smith & Nephew


• Dr PRP USA LLC

Spine Biologics Industry Developments

In October 2022 The first patient to get invasive spinal colon surgery in Japan had treatment at the International University of Health and Wellness at Mita Hospital in Tokyo using Royal Philips' Augmented Reality (A.R.) surgical navigation tool, ClarifEye, emphasizing the successful post-operative outcomes.

In February 2020 The SeaSpine holding firm joined forces strategically with 7DSurgical Inc. to concentrate on surgical treatments for spinal ailments.

In May 2020 The Modulus XLIF Dual-sided plate was introduced by NuVasive, a pioneer in spine technology, and was given 510(k) clearance by the US Food and Drug Administration.

In August 2018 Aziyo Biologics was in agreement with RTI Surgical Holding Inc. In accordance with the agreement, Aziyo Company provides RTI Surgical with assistance for its ViBone device, which is used to mend bone during auto-graft procedures for various orthopedic surgeries.

Spine Biologics Market Segmentation

Spine Biologics Product Outlook

• Bone Allografts


• Bone Graft Substitute


• Platelet Rich Plasma


• Bone Marrow Aspirate Therapy

Spine Biologics Surgery Type Outlook

• Anterior Cervical Discectomy and Fusion (ACDF)


• Transforamenal Lumbar Interbody Fusion (TLIF)


• Anterior Lumbar Interbody Fusion (ALIF)


• Lateral Lumbar Interbody Fusion (LLIF)

Spine Biologics End User Outlook

• Hospitals


• Spinal Surgery Centers


• Orthopedic Clinics,


• Others

Spine Biologics Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World

• 
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America